Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

760 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetics, Mass Balance, Safety, and Tolerability of Obeldesivir in Healthy Participants.
Anoshchenko O, Abdelghany M, Lichtman A, Duan R, Chen H, Shaik NA, Peng CC, Yue Q, Subramanian R, Hyland RH, Davies S, Castellanos K, Mak L, Shen G, Xiao D, Caro L, Winter H, Llewellyn J, Humeniuk R. Anoshchenko O, et al. Among authors: subramanian r. Clin Pharmacol Ther. 2024 Nov;116(5):1231-1239. doi: 10.1002/cpt.3337. Epub 2024 Jun 28. Clin Pharmacol Ther. 2024. PMID: 38940465 Clinical Trial.
Lenacapavir: A Novel, Potent, and Selective First-in-Class Inhibitor of HIV-1 Capsid Function Exhibits Optimal Pharmacokinetic Properties for a Long-Acting Injectable Antiretroviral Agent.
Subramanian R, Tang J, Zheng J, Lu B, Wang K, Yant SR, Stepan GJ, Mulato A, Yu H, Schroeder S, Shaik N, Singh R, Wolckenhauer S, Chester A, Tse WC, Chiu A, Rhee M, Cihlar T, Rowe W, Smith BJ. Subramanian R, et al. Mol Pharm. 2023 Dec 4;20(12):6213-6225. doi: 10.1021/acs.molpharmaceut.3c00626. Epub 2023 Nov 2. Mol Pharm. 2023. PMID: 37917742 Free PMC article.
Discovery of GS-5245 (Obeldesivir), an Oral Prodrug of Nucleoside GS-441524 That Exhibits Antiviral Efficacy in SARS-CoV-2-Infected African Green Monkeys.
Mackman RL, Kalla RV, Babusis D, Pitts J, Barrett KT, Chun K, Du Pont V, Rodriguez L, Moshiri J, Xu Y, Lee M, Lee G, Bleier B, Nguyen AQ, O'Keefe BM, Ambrosi A, Cook M, Yu J, Dempah KE, Bunyan E, Riola NC, Lu X, Liu R, Davie A, Hsiang TY, Dearing J, Vermillion M, Gale M Jr, Niedziela-Majka A, Feng JY, Hedskog C, Bilello JP, Subramanian R, Cihlar T. Mackman RL, et al. Among authors: subramanian r. J Med Chem. 2023 Sep 14;66(17):11701-11717. doi: 10.1021/acs.jmedchem.3c00750. Epub 2023 Aug 19. J Med Chem. 2023. PMID: 37596939 Free PMC article.
Human pharmacokinetics prediction with an in vitro-in vivo correction factor approach and in vitro drug-drug interaction profile of bictegravir, a potent integrase-strand transfer inhibitor component in approved biktarvy® for the treatment of HIV-1 infection.
Subramanian R, Wang J, Murray B, Custodio J, Hao J, Lazerwith S, MacLennan Staiger K, Mwangi J, Sun H, Tang J, Wang K, Rhodes G, Wijaya S, Zhang H, Smith BJ. Subramanian R, et al. Xenobiotica. 2022 Dec;52(12):1020-1030. doi: 10.1080/00498254.2023.2169207. Epub 2023 Jan 26. Xenobiotica. 2022. PMID: 36701274 Free article.
FORCE platform overcomes barriers of oligonucleotide delivery to muscle and corrects myotonic dystrophy features in preclinical models.
Weeden T, Picariello T, Quinn B, Spring S, Shen PY, Qiu Q, Vieira BF, Schlaefke L, Russo RJ, Chang YA, Cui J, Yao M, Wen A, Hsia N, Evron T, Ovington K, Tsai PN, Yoder N, Lan B, Venkatesan R, Hall J, Desjardins CA, Qatanani M, Hilderbrand S, Najim J, Tang Z, Tanner MK, Subramanian R, Thornton CA, Ibraghimov-Beskrovnaya O, Zanotti S. Weeden T, et al. Among authors: subramanian r. Commun Med (Lond). 2025 Jan 18;5(1):22. doi: 10.1038/s43856-025-00733-w. Commun Med (Lond). 2025. PMID: 39827287 Free article.
760 results